AI Image
Community supports Beaverton teacher with cancer after insurance denies coverage
KPTV • • health
Key Points:
- Niki Taylo, a teacher diagnosed with Stage IV endometrial cancer, faced insurance denials from Regence Blue Cross Blue Shield for the targeted cancer drug ENHERTU, which her oncologist recommended after traditional treatments failed.
- After two denials and a rejected financial assistance application, Taylo and her husband launched a community fundraiser that quickly surpassed their $75,000 goal, while supporters also organized an email campaign to pressure the insurer.
- Following community advocacy, Regence contacted Taylo's medical provider and ultimately approved coverage for ENHERTU through the ENHERTU4 program, allowing Taylo to begin treatment.
- The Taylos expressed gratitude for the support but frustration that extensive community intervention was necessary to secure medically recommended care, highlighting challenges in accessing expensive treatments.
- Regence stated its commitment to evidence-based care and personalized support during appeals, confirming Taylo's case is under independent review, and emphasized privacy limits on public commentary.
